How does OMAI's multi-agentic system compare to other AI tools in drug development, given the black-box nature of many competitors?

OMAI uses an orchestrated multi-agentic system for various tasks (literature synthesis, medicinal chemistry, etc.), allowing for real-time transparency and user tweakability, unlike older monolithic models. This approach is positioned to disrupt traditional software providers and reduce the need for large bioinformatics teams. “We now see that things are moving well beyond a single line of questioning or query. So we've built an orchestrated system. And this orchestra brings together specialized agents for literature synthesis, medicinal chemistry, pathway analysis, data curation, literature analysis, portfolio prioritization, clinical trial development and that -- and they challenge each other, and they pass information and ideas, and they cross-validate before delivering hardened results or ask the scientists or drug developer to get more engaged and ask them questions.”

Is there interest in withZeta from large pharma companies?

Yes, large pharma companies, both biologic and small molecule groups, have shown significant interest, with calls and visits. Management expects increased interest with more marketing. “The quick answer is, yes. We've got a lot of pharma companies, both biologic groups as well as small molecule groups. We've had some -- had several calls with us, some visit. So the answer is, yes. Large pharma is definitely interested.”

How does Lantern ensure OMAI's models become industry standards and prevent competitors from copying methods?

While competitors will copy, separating OMAI allows it to move faster and raise independent capital to stay ahead. The strategy focuses on going deep in specific, tough challenges like rare cancers and bio-computational tools, rather than broad across all science. “The things that we're doing in addition to continuing to train our models and try to grow intelligently using our center in Bangalore, India. Those are things that we're doing. We're also constantly benchmarking like we did with our BBB algorithm like we're doing with our bio-computational tools. We're trying to pick some of the toughest challenges and go deep as opposed to go broad.”

LTRN

Lantern Pharma (LTRN) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 14, 2026

Source: earnings call transcript

Executive summary

Lantern Pharma Q2 FY26 — AI Engine Spin-Out and Clinical Progress

Lantern Pharma is undergoing a significant structural transformation, spinning out its AI engine into a new company, Open Medicine AI, to unlock value and accelerate its commercialization. Concurrently, the company continues to advance its clinical pipeline with promising data from the LP-300 HARMONIC trial, regulatory clearances for LP-184, and progress in its pediatric oncology programs, all while maintaining disciplined cost management despite increased net losses driven by non-cash warrant expenses.

Highlights

Established Open Medicine AI as a separate company with commercial licenses, poised to operate multi-agentic AI co-scientists.
Achieved a 25% reduction in total operating expenses year-over-year while advancing multiple clinical programs.
LP-300 HARMONIC trial showed median progression-free survival of 8.9 months in L858R patients completing 6 cycles, with a 77% clinical benefit rate.
LP-184 received EMA clearance for a Phase Ib/II trial in advanced bladder cancer and FDA clearance for a Phase Ib/II trial in triple-negative breast cancer.
Received a notice of allowance for a patent covering a 3-gene selection method for LP-184 in ovarian, liver, kidney, and thyroid cancers.

Concerns

Net loss increased to $7.1 million or $0.57 per share for Q2 FY26, primarily due to a $3.6 million noncash warrant expense.
Cash, cash equivalents, and marketable securities decreased to $7.4 million at June 30, 2026, from $10.1 million at December 31, 2025.
The company intends to pursue additional capital raises, collaborations, and other opportunities to extend its operating runway.
LP-300 data from small exploratory cohorts are not yet powered for statistical significance.

Guidance & targets

Category	Target	Timeline	Confidence
LP-300 HARMONIC trial enrollment	15-16 additional patients medium materiality	Next 4 to 6 months	High
Open Medicine AI market potential (analyst projection)	$10 billion high materiality	by 2030-2031 · FY30-FY31	Medium
Open Medicine AI market potential (internal projection)	$9 billion to $10-plus billion high materiality	by 2031 · FY31	Medium
Open Medicine AI informational call	Dedicated informational call medium materiality	mid-September	High
Starlight program funding	Additional funding medium materiality	Ongoing	High
Pediatric oncology program data update	More data medium materiality	Q3 FY26	High

Deals & partnerships

Open Medicine AI Establishment of a separate company with commercial licenses and agreements from Lantern Pharma.

Formally established in August 2026. OMAI will operate multi-agentic AI co-scientists. Longer-term objective is to become a separately listed company. Potential distribution of OMAI shares to Lantern shareholders being explored.

Starlight Starlight (STAR-001 program) established as a separate funding entity.

Starlight is a template for monetizing programs independently of the rest of Lantern. It is a way to monetize the LP-184 program in brain cancers.

Risks & headwinds

Need for additional funding Near-term

Cash, cash equivalents and marketable securities were approximately $7.4 million at June 30, 2026, compared to approximately $10.1 million as of December 31, 2025.

Mitigation:Intends to pursue additional capital raises, collaborations, and other opportunities to extend operating runway.

Clinical trial outcomes and competition Ongoing

Actual results may differ materially from forward-looking statements.

Mitigation:Not explicitly stated, but implies continued focus on data-driven development and strategic partnering.

Statistical significance of early clinical data Near-term to medium-term

LP-300 data from small exploratory cohorts are not powered for statistical significance yet.

Mitigation:Amended trial protocol to concentrate enrollment on L858R patients and extend treatment cycles, aiming for more meaningful data with additional patients.

What to watch in Q3 FY26

LP-300 HARMONIC trial enrollment

Next 4-6 months

Current Enrollment resuming under new protocol

Target 15-16 additional patients enrolled

Why it matters

Verifies progress in the key clinical trial and provides more data for statistical significance.

We expect to be enrolling patients in Taiwan and the U.S., specifically under the new amended protocol. We hope to expect another 15, 16 patients that will give us meaningful data, and we expect to enroll those over the next 4 to 6 months, both in the U.S. and Taiwan.

Find out whether LTRN delivers this. Inve re-checks your case every morning.

Q&A highlights

How mature is the LP-300 data set, when will it be updated, and have patients been enrolled under the new protocol?

Enrollment under the new 8-cycle protocol is expected to resume in the U.S. and Taiwan after IRB approvals, targeting 15-16 additional patients over 4-6 months. A further update on the current cohort may come by year-end.

“We expect to be enrolling patients in Taiwan and the U.S., specifically under the new amended protocol. We hope to expect another 15, 16 patients that will give us meaningful data, and we expect to enroll those over the next 4 to 6 months, both in the U.S. and Taiwan.”

asked by Unknown Analyst · answered by Panna Sharma

3 min read 6 chapters

Detailed narrative

Open Medicine AI Spin-Out and Strategic Rationale

Lantern Pharma formally established Open Medicine AI (OMAI) as a separate company in August 2026, complete with commercial licenses and agreements. This strategic move aims to leverage OMAI's multi-agentic AI co-scientists in a commercial setting, moving beyond single-model AI approaches.

The company believes this orchestrated system, which integrates specialized agents for various drug discovery tasks, will become the standard infrastructure for multidisciplinary drug discovery, offering transparency and audit trails. The separation is driven by the differing valuation metrics for clinical drug development and enterprise software, allowing OMAI to raise its own capital and pursue its commercial model independently, while Lantern retains 100% ownership initially and full access to the platform for its own drug development.

LP-300 HARMONIC Trial Progress and Protocol Amendments

The Phase II HARMONIC trial for LP-300 in never-smokers with non-small cell lung cancer (NSCLC) showed promising emerging data, particularly in L858R patients. Among those completing 6 cycles, median progression-free survival (PFS) reached 8.9 months, with a 77% clinical benefit rate and over 70% target lesion reduction.

The trial protocol has been amended to concentrate enrollment on L858R patients, extend treatment from 6 to 8 cycles, and adopt a single-arm design for increased efficiency and reduced cost. Enrollment is expected to resume in the U.S. and Taiwan, targeting 15-16 additional patients over the next 4-6 months.

LP-184 Advancements and Regulatory Milestones

LP-184 achieved several significant milestones, including EMA clearance in July 2026 for an investigator-initiated Phase Ib/II trial in advanced bladder cancer at Rigshospitalet in Copenhagen. This 39-patient trial will focus on a dual biomarker strategy. The FDA also cleared a Phase Ib/II trial for LP-184 monotherapy in relapsed or refractory triple-negative breast cancer, which will enroll up to 40 patients across two dose cohorts.

Furthermore, Lantern received a notice of allowance in July for a patent covering a 3-gene selection method (PTGR1, PTPN14, ASPH) to identify patients most likely to respond to LP-184 in ovarian, liver, kidney, and thyroid cancers.

LP-284 and Starlight Pediatric Oncology Programs

LP-284 continues its development in hematologic malignancies and adult soft tissue sarcomas, having secured orphan designation earlier in the year. The Starlight program (STAR-001), which utilizes LP-184 for brain cancers, has demonstrated strong preclinical data by targeting ERCC3 protein degradation using spironolactone.

Starlight is 100% owned by Lantern, holds its own INDs and regulatory designations, and is being advanced for rare pediatric brain tumors such as ATRT, hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors. Each of these indications is independently eligible for a priority review voucher, valued at $150 million to $200 million or more, with Lantern holding four such potential vouchers.

Financial Discipline and Operating Model Efficiency

Lantern Pharma reported a 25% reduction in total operating expenses year-over-year, reflecting highly disciplined execution despite advancing multiple clinical programs and launching OMAI. The company emphasizes its efficient operating model, which enables the progression of programs from AI-derived insights to first-in-human clinical trials in under three years and at a cost of approximately $2 million to $3 million per program, significantly below the industry norm of 5-10 years and $25 million to $100 million.

This efficiency, coupled with three molecules in clinical trials and over 100 patients dosed, underpins Lantern's core advantage.

Future Outlook and Monetization Strategy

The remainder of 2026 is considered a defining year for Lantern Pharma, with a planned launch in 2027. The company views its business model, which integrates a clinically validated platform with three drugs in trials and a commercially accessible AI platform, as a powerful complement.

The AI tools and services are projected to grow into several hundred million dollars in stand-alone value within the larger $10 billion market for AI in drug discovery. Lantern is exploring ways to distribute OMAI shares to its shareholders, allowing them to benefit from its monetization through private financings and a potential public listing.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.